Skip to main content

Advanced Search

Haematologica
  • Home
  • Current Issue
  • Ahead Of Print
  • Archive
  • Submit a Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Submit a Manuscript
    • Track a Manuscript
  • About Us
    • About Haematologica
    • Editorial Board
    • Our Policies
  • More
    • Advertising
    • Rights & Permissions
    • Alerts
    • Feedback
    • Contact
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone
Daniel O. Persky, David Dornan, Bryan H. Goldman, Rita M. Braziel, Richard I. Fisher, Michael LeBlanc, David G. Maloney, Oliver W. Press, Thomas P. Miller, Lisa M. Rimsza
Haematologica June 2012 97: 937-942; doi:10.3324/haematol.2011.050419
Daniel O. Persky
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dpersky@azcc.arizona.edu
David Dornan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bryan H. Goldman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rita M. Braziel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard I. Fisher
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael LeBlanc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David G. Maloney
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oliver W. Press
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas P. Miller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa M. Rimsza
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site

Author Affiliations

  1. Daniel O. Persky1⇓,
  2. David Dornan2,
  3. Bryan H. Goldman3,
  4. Rita M. Braziel4,
  5. Richard I. Fisher5,
  6. Michael LeBlanc3,
  7. David G. Maloney6,
  8. Oliver W. Press6,
  9. Thomas P. Miller1 and
  10. Lisa M. Rimsza7
  1. 1Arizona Cancer Center, University of Arizona, Tucson, AZ
  2. 2Research Oncology Diagnostics, Genentech Inc., South San Francisco, CA
  3. 3Southwest Oncology Group Statistical Office, Seattle, WA
  4. 4Clinical Pathology, Oregon Health & Science University, Portland, OR
  5. 5James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY
  6. 6Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
  7. 7Department of Pathology, University of Arizona, Tucson, AZ, USA
  1. Correspondence: Daniel O. Persky, MD, Arizona Cancer Center, University of Arizona, 1515 N Campbell Avenue, Tucson, AZ 85724-5024, USA. Phone: international +1.520.626-2218. Fax: international +1.520.626-2225. E-mail: dpersky{at}azcc.arizona.edu.
View Abstract
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Data supplements

  • Disclosures and Contributions

    Files in this Data Supplement:

    • Adobe PDF - 2011_050419-Disclosures.pdf
    • Adobe PDF - 2011_050419-Contributions.pdf

ARTICLE FIGURES & DATA

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    (A) Overall survival (OS) by FCGR3A genotype for the chemotherapy only trial, S8809. (B) Overall survival (OS) by FCGR3A genotype for the chemotherapy + mAb trials, S9800 and S9911 (B). Kaplan-Meier curves, with follow up truncated at ten years. 158 F/F (unfavorable) genotype denoted by solid line; 158 V/F genotype denoted by dotted line; 158 V/V genotype denoted by dashed line.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    (A) Progression-free survival (PFS) by FCGR3A 158 genotype for the chemotherapy only trial, S8809. (B) Progression-free survival (PFS) by FCGR3A 158 genotype for the chemotherapy + mAb trials, S9800 and S9911. Kaplan-Meier curves, with follow up truncated at ten years. 158 F/F (unfavorable) genotype denoted by solid line; 158 V/F genotype denoted by dotted line; 158 V/V genotype denoted by dashed line.

Tables

  • Figures
  • Table 1.

    Patient’s characteristics across clinical trials.

    Table 1.
  • Table 2.

    Fc gamma receptor 3A polymorphism studies in follicular lymphoma.

    Table 2.
PreviousNext
Back to top

Vol 97 Issue 6

Haematologica: 97 (6)

Issue highlights

  • Optimisation of investigator-led oncology research in Europe
  • MicroRNA126 contributes to G-CSF-induced hematopoietic progenitor cell mobilization by reducing VCAM-1 expression
  • Cytopenia and leukocyte recovery shape cytokine fluctuations after myeloablative allogeneic hematopoietic stem cell transplantation
  • Clinical cardiac safety profile of nilotinib
  • PET/CT surveillance in patients with Hodgkin lymphoma in first remission is associated with low positive predictive value and high costs
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word about Haematologica.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone
(Your Name) has forwarded a page to you from Haematologica
(Your Name) thought you would like to see this page from the Haematologica web site.
Print
Citation Tools
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone
Daniel O. Persky, David Dornan, Bryan H. Goldman, Rita M. Braziel, Richard I. Fisher, Michael LeBlanc, David G. Maloney, Oliver W. Press, Thomas P. Miller, Lisa M. Rimsza
Haematologica Jun 2012, 97 (6) 937-942; DOI: 10.3324/haematol.2011.050419

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Daniel O. Persky, David Dornan, Bryan H. Goldman, Rita M. Braziel, Richard I. Fisher, Michael LeBlanc, David G. Maloney, Oliver W. Press, Thomas P. Miller, Lisa M. Rimsza
Haematologica Jun 2012, 97 (6) 937-942; DOI: 10.3324/haematol.2011.050419
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Request Permissions
  • Tweet Widget
  • Facebook Like
  • Alert me when this article is cited
  • Alert me if a correction is posted

Jump To

  • Article
    • Abstract
    • Introduction
    • Design and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

What about you?
Tell us your interests and get all the new contents of Haematologica in advance

 

 

Navigate

  • Home
  • Current issue
  • Ahead of print
  • Archive
  • Info for
    • Authors
    • Reviewers
    • Advertisers
    • Subscribers
  • About us
    • About Haematologica
    • Editorial Board
    • Our policies

For Authors

  • Author guidelines
  • Submit Manuscript
  • Track Manuscript

For Reviewers

  • Reviewer Guidelines
  • Access Your Profile
  • Access Your Tasks
  • 2014 reviewers

For Advertisers

  • Information For Advertising

Education

  • Review Articles
  • Guideline Articles

More

  • Rights & Permissions
  • Advertising
  • Alerts
  • Feedback
  • Contact
  • App

Copyright © 2019 by the Ferrata Storti Foundation

ISSN 0390-6078 print

ISSN 1592-8721 online